VEGFA and hepatocellular carcinoma: Initially applied mainly for patients after tumor progression in first or second line of systemic treatment, the results of the IMbrave150 trial led to a paradigm change and the combination of the checkpoint inhibitor atezolizumab and the VEGF antibody bevacizumab is now the first line treatment for patients with advanced HCC [5–7].